Drug Trial Radar · NCT05370820
Prevention of Postpartum Hemorrhage With Tranexamic Acid
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Dec 28, 2022
Primary completion
Oct 1, 2027
Study completion Apr 1, 2028
Sponsor
- Lead sponsor
- Inova Health Care ServicesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- George Washington University; University of Maryland; University of North Carolina; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- First posted
- May 12, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
In part 1 of the study, the investigators conducted a prospective, open-label, dose finding pharmacokinetic (PK) study in 43 pregnant 3rd trimester women scheduled for non-emergent cesarean section. The investigators administered three doses of the drug (5 mg/kg, 10 mg/kg and 15 mg/kg) in an escalating fashion by cohort with the lowest dose first. The drug was administered intravenously at the time of umbilical cord clamping for a non-emergent cesarean section. A maximum of 1 g was administered. TXA serum levels at several time points after delivery were assayed to see if they reach the target plasma concentration of 10 ug/mL. A PK model was constructed for determining the optimal TXA dose administered at parturition. In part 2 of the study, the investigators aim to compare PKPD endpoints using prophylactic TXA via IV and IM routes administered pre-cord clamp. The investigators will administer 1 g TXA within 10 minutes of skin incision via intravenous infusion (up to n=15), intravenous bolus \< 2 minutes (up to n=15) and intramuscular injection (up to n=15). The investigators will target women undergoing scheduled cesarean delivery \> 34 weeks gestation, women undergoing vaginal delivery \> 34 weeks of gestation and morbidly obese women (BMI\>=40) undergoing either a vaginal or cesarean delivery. The investigators will use advanced modeling techniques to determine time to achieve PKPD targets and duration remaining at those targets. The goal will be to determine how the optimal dose may vary if route of administration is modified. The investigators plan to enroll 45 patients in addition to the 43 that were enrolled during part 1. Our goal is to 30 participants, but the investigators will enroll 45 to account for lost to follow-up. The investigators also aim to enroll 30 patients undergoing vaginal delivery and 30 morbidly obese women (BMI \>= 40) undergoing either a vaginal or cesarean delivery but the investigators will enroll 45 patients for each of these groups to account for loss to follow up. In addition, the investigators will enroll 30 pregnant patients receiving no medication acting as the control group, but the investigators will enroll 45 to account for loss to follow up.
Conditions
- Post Partum Hemorrhage
Interventions
Tranexamic acidDrug
Tranexamic Acid 1000 mg administered intravenously via infusion over 10 minutes.
Tranexamic acidDrug
Tranexamic Acid 1000 mg administered intravenously via push over 2 minutes.
Tranexamic acidDrug
Tranexamic Acid 1000 mg administered intramuscularly.
No interventionOther
Control group with no administration of Tranexamic Acid.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PK Model Parameter EstimatesTime frame: Different time points ranging from surgery (T0) to 1 day postpartum.
- Pharmacodynamics of Tranexamic AcidTime frame: Different time points ranging from surgery (T0) to 1 day postpartum.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
George Washington University Hospital
Washington D.C., District of Columbia · Recruiting
Inova Fairfax Medical Campus
Falls Church, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.